Dr. Monica Mita, MD
Claim this profileCedars-Sinai Medical Center
Expert in Breast Cancer
Studies Solid Tumors
22 reported clinical trials
37 drugs studied
Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
2Solid Tumors
Stage IV
Stage III
EGFR negative
Affiliated Hospitals
Clinical Trials Monica Mita, MD is currently running
Evexomostat + Alpelisib + Fulvestrant
for Breast Cancer
This trial tests a new drug combination for post-menopausal women with a specific type of advanced breast cancer. It aims to see if the new drug can reduce side effects and improve the effectiveness of existing treatments. The treatment works by blocking proteins and hormones that help cancer grow and by managing side effects like high blood sugar.
Recruiting1 award Phase 1 & 211 criteria
OBT076
for Advanced Cancer
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.
Recruiting1 award Phase 115 criteria
More about Monica Mita, MD
Clinical Trial Related7 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Monica Mita, MD has experience with
- Pembrolizumab
- Nivolumab
- Ladiratuzumab Vedotin
- RT Boost
- Pentostatin
- Cordycepin
Breakdown of trials Monica Mita, MD has run
Breast Cancer
Solid Tumors
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Monica Mita, MD specialize in?
Monica Mita, MD focuses on Breast Cancer and Solid Tumors. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Monica Mita, MD currently recruiting for clinical trials?
Yes, Monica Mita, MD is currently recruiting for 9 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Monica Mita, MD has studied deeply?
Yes, Monica Mita, MD has studied treatments such as Pembrolizumab, Nivolumab, ladiratuzumab vedotin.
What is the best way to schedule an appointment with Monica Mita, MD?
Apply for one of the trials that Monica Mita, MD is conducting.
What is the office address of Monica Mita, MD?
The office of Monica Mita, MD is located at: Cedars-Sinai Medical Center, Los Angeles, California 90048 United States. This is the address for their practice at the Cedars-Sinai Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.